CDAI Calculator
Calculate the CDAI score to assess Crohn's disease severity using eight clinical and laboratory parameters. Free online medical tool with component breakdown and charts.
About This Calculator
The Crohn's Disease Activity Index (CDAI) Calculator is a standardized clinical tool designed to quantify the severity of symptoms in patients with Crohn's disease. Developed in 1976 by experts at the Midwest Regional Health Center in Illinois, the CDAI has become the most widely used disease activity index in clinical research and trials for Crohn's disease worldwide. This evidence-based scoring system helps healthcare professionals assess disease activity objectively and monitor response to treatment over time.
The CDAI score is calculated using eight weighted determinants that capture the multi-system effects of Crohn's disease. The components and their weighting factors are: number of liquid stools in the past 7 days (×2), average daily abdominal pain score from 0 to 3 (×5), average daily general well-being score from 0 to 4 (×7), number of extra-intestinal complications present from a list of six (×20 each), antidiarrheal medication use in the past 7 days (×30), abdominal mass rated as 0 none, 2 questionable, or 5 definite (×10), hematocrit deficit using sex-specific reference values (47% for men, 42% for women, ×6), and percentage deviation from standard body weight (×1). The total score can range from 0 to over 600, with higher scores indicating greater disease activity.
A CDAI score below 150 indicates clinical remission. Scores between 150 and 450 indicate active disease of varying severity, and scores above 450 indicate severe disease requiring urgent intervention. A decrease of more than 70 points is considered a clinically significant treatment response. The CDAI is most commonly measured at baseline and at regular intervals (e.g., every 4-8 weeks) during treatment to track disease progression and therapeutic efficacy. It is particularly important as a primary endpoint in clinical trials evaluating new biologic agents and small molecule therapies for Crohn's disease.
Regional Notes
India: Crohn's disease incidence is rising in India, particularly in urban populations. Indian gastroenterologists commonly use the CDAI alongside endoscopic activity indices (SES-CD), C-reactive protein (CRP), and fecal calprotectin for comprehensive disease assessment. Biologic therapies including infliximab and adalimumab are available through specialty gastroenterology centers in major cities. The Indian Society of Gastroenterology recommends regular disease activity monitoring for patients on biologic therapy.
United States: In the US, the CDAI is accepted by the FDA as a validated primary endpoint for Crohn's disease clinical trials and is widely used in gastroenterology practice. The American Gastroenterological Association (AGA) recognizes the CDAI as a standard disease activity measure. Biologic therapies including TNF inhibitors (infliximab, adalimumab, certolizumab), integrin inhibitors (vedolizumab), and IL-12/23 inhibitors (ustekinumab) are commonly prescribed based on CDAI scores and endoscopic findings.
United Kingdom: NICE guidelines reference the CDAI for assessing treatment response in Crohn's disease. In the NHS, the CDAI is used alongside endoscopic and radiological assessments to determine eligibility for biologic therapies under NICE TA352 (infliximab, adalimumab) and later technology appraisals. Patients with moderate to severe active Crohn's disease (CDAI 220-450) who have failed conventional therapy may qualify for biologic treatment.
This tool is intended for educational and clinical reference. Always consult a qualified gastroenterologist for diagnosis and treatment of Crohn's disease.
Frequently Asked Questions
What is the CDAI score?
The Crohn's Disease Activity Index (CDAI) is a clinical research tool developed in 1976 by experts at the Midwest Regional Health Center in Illinois to quantify the severity of symptoms in patients with Crohn's disease. It consists of eight weighted determinants including stool frequency, abdominal pain, general well-being, complications, medication use, abdominal mass, hematocrit, and weight deviation.
How is the CDAI score calculated?
The CDAI score is calculated by summing eight weighted components: (1) Number of liquid stools × 2, (2) Average abdominal pain (0-3) × 5, (3) Average general well-being (0-4) × 7, (4) Number of extra-intestinal complications × 20, (5) Antidiarrheal use (0/1) × 30, (6) Abdominal mass (0/2/5) × 10, (7) Hematocrit deficit × 6, and (8) Weight deviation percentage × 1. The hematocrit deficit is calculated as 47% minus actual for men or 42% minus actual for women.
How is the CDAI score interpreted?
CDAI scores are interpreted as follows: below 150 indicates remission of Crohn's disease where the disease is well-controlled; 150 to 450 indicates active disease requiring potential treatment adjustment; above 450 indicates severe disease requiring urgent medical evaluation. A decrease in CDAI score greater than 70 points is considered a clinically significant response to treatment.
What are the eight components of the CDAI?
The CDAI consists of eight weighted determinants: number of liquid or very soft stools in the past 7 days (×2); average abdominal pain severity on a scale of 0 to 3 over 7 days (×5); average general well-being on a scale of 0 to 4 over 7 days (×7); presence of extra-intestinal complications including arthritis, uveitis, skin disease, anal lesions, fistulae, or fever (×20 each); antidiarrheal medication use (×30); abdominal mass rated as none/questionable/definite (×10); hematocrit deficit using sex-specific reference values (×6); and deviation from standard body weight (×1).
What extra-intestinal complications are included in the CDAI?
The CDAI includes six extra-intestinal complications: arthritis or arthralgia (joint pain); iritis or uveitis (eye inflammation); skin disease including erythema nodosum, pyoderma gangrenosum, or aphthous ulcers; anal fissures, fistulae, or abscesses; other fistulae; and fever in the past 7 days with body temperature higher than 100°F (37.8°C). Each complication present adds 20 points to the total score.
Is the CDAI used in clinical practice worldwide?
Yes, the CDAI is the most widely used disease activity index for Crohn's disease in clinical trials and research worldwide. It has been validated in multiple populations. In India, gastroenterologists commonly use the CDAI alongside endoscopic findings and inflammatory markers like CRP and fecal calprotectin for comprehensive disease assessment. In the US, the CDAI is accepted by the FDA as a primary endpoint in clinical trials. In the UK, NICE guidelines reference the CDAI for assessing treatment response in biologic therapy.
What is a clinically significant response in CDAI?
A decrease in the CDAI score of more than 70 points from baseline is considered a clinically meaningful improvement and indicates response to treatment. A reduction to below 150 points is defined as clinical remission. These thresholds are used as primary endpoints in clinical trials evaluating new therapies for Crohn's disease, including biologic agents and small molecule drugs.
Can I rely on this calculator for medical decisions?
No. This calculator is for educational and reference purposes only. The CDAI is a clinical assessment tool and should be calculated by a qualified gastroenterologist. It should never replace a comprehensive medical evaluation. Always consult a healthcare professional for diagnosis, treatment decisions, and management of Crohn's disease.